Pharmaceuticals, Biotechnology and Life Sciences
Johnson & Johnson has had sales of $17.1 billion for the third quarter of 2015, a decrease of 7.4% as compared to the third quarter of 2014.
Johnson & Johnson has started a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies.
Johnson & Johnson has announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments.
Johnson & Johnson has completed the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion.
Johnson & Johnson Consumer Inc. has completed the divestiture of Splenda Brand to Heartland Food Products Group. Johnson & Johnson announced…